SEC Filing Summary: AVI BioPharma, Inc. (10-K)
Business Context and Reporting Period
Company: AVI BioPharma, Inc. (Note: Input metadata referenced "Sarepta Therapeutics," but the filing text identifies the registrant as AVI BioPharma, Inc.)
Period: Fiscal year ended December 31, 2001
Industry: Biopharmaceutical (Development Stage)
Core Technologies: NEUGENE (antisense drugs) and Avicine (cancer vaccine).
Operations: The company is in the development stage with no commercial products. It focuses on pre-clinical and clinical trials for cardiovascular disease, cancer, and drug metabolism. The company relies on strategic partnerships (SuperGen, Medtronic, Exelixis) for funding and future commercialization.
Key Financial Metrics (Year Ended Dec 31, 2001)
| Metric | 2001 | 2000 |
|---|---|---|
| Revenues | $706,102 | $1,297,338 |
| Net Loss | $(26,925,174) | $(9,239,956) |
| Net Loss Per Share | $(1.20) | $(0.49) |
| Research & Development Expenses | $12,750,901 | $9,268,330 |
| Cash and Cash Equivalents | $11,069,451 | $25,898,513 |
| Total Assets | $33,815,113 | $35,088,393 |
| Working Capital | $24,230,010 | $31,408,473 |
| Accumulated Deficit | $(87,219,007) | $(60,293,833) |
Note: The 2001 Net Loss includes a non-cash write-down of $12,523,088 related to an investment in SuperGen, Inc.
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased 45% from $1.30 million in 2000 to $0.71 million in 2001. The 2000 figure included a one-time $1 million license fee expansion payment not repeated in 2001.
- Increased Operating Expenses: Total operating expenses rose to $16.1 million in 2001 from $11.5 million in 2000, driven by increased R&D staffing and clinical trial costs.
- Investment Impairment: A significant non-cash charge of $12.5 million was recorded in Q3 2001 due to an "other than temporary impairment" of the company's investment in SuperGen stock.
- Cash Position: Cash and cash equivalents decreased by approximately $14.8 million year-over-year, primarily due to operating cash burn of $12.8 million and capital expenditures for property, equipment, and patents.
Guidance, Outlook, and Risks
Outlook: Management expects to continue incurring losses for the foreseeable future. No material product revenues are expected for at least the next 12 months. Estimated expenditures for 2002 are projected to exceed $20 million.
Capital Needs: The company raised approximately $23 million in a private equity financing on March 25, 2002 (post-fiscal year end). Management states that existing cash resources are sufficient for at least the next 12 months, but additional capital will be required to fund operations beyond that period.
Key Risks:
- Regulatory Approval: Products are subject to extensive FDA regulation; failure to obtain approval will prevent commercialization.
- Development Risk: Clinical trials may fail to demonstrate safety or efficacy (e.g., Phase III trials for Avicine are ongoing).
- Liquidity: Dependence on equity financing and strategic partners; inability to raise capital could force curtailment of operations.
- Partnership Dependence: Success relies heavily on partners like SuperGen and Medtronic to fund late-stage trials and marketing.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $23 million raised in March 2002 against the projected $20+ million annual burn rate.
- SuperGen Investment: Assess the current fair value and liquidity of the remaining SuperGen investment ($6.4 million at year-end) given the prior impairment.
- Clinical Trial Status: Monitor progress of the Phase III trial for Avicine (colorectal cancer) and Phase II trials for Resten-NG (cardiovascular).
- Partnership Milestones: Review the status of milestone payments and obligations under agreements with SuperGen, Medtronic, and Exelixis.
- Dilution Risk: Evaluate the impact of outstanding warrants (10.3 million shares) and options (2.9 million shares) on future share count.